How much wiggle room do sponsors have when the US FDA asks them to conduct pediatric studies? The question is again at issue in Amgen Inc.'s suit against FDA objecting to the agency's denial of pediatric exclusivity for Sensipar (cinacalcet).
The complaint specifically addresses when studies "fairly respond" to the agency's written request for them. FDA contends that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?